Трекрезан

Relieves ARVI symptoms:

headache

chills

fever

runny nose

muscle pain

And unlike other products, it regenerates energy after illness to 100%.

Instruction for use Watch the video

Up to 90% of people experience symptoms of asthenia even after recovery – fatigue, weakness, lack of energy.

unlike other products,

Trekrezan® not only treats colds, but also regenerates energy after illness to 100%

Dual mode of action

Immunomodulatory properties

stimulates the production of α- and γ-interferons, providing rapid and long-term antiviral effect¹

reduces the duration of ARVI by an average of 2.2 days²

activates cellular and humoral immunity

Adaptogenic properties

eliminates post-infectious asthenia (fatigue, weakness, lack of energy) after illness³

increases the body resistance to adverse external factors and stress

improves performance efficiency under vigorous physical activity and high mental workload

the only product

with dual immunomodulatory and adaptogenic effects¹

tested
in > 40

clinical and post-marketing surveillance studies²

Included

in the Ministry of Health's draft Clinical Guidelines for the treatment of ARVI³

in the TOP 3 in sales by package

among antiviral and immunomodulatory drugs in the Russian Federation⁴

> 35 million

packages of Trekrezan® sold since 2018⁴

Watch the video

Indications for use

for prevention and treatment of acute respiratory viral infections

during periods of high mental work load and vigorous physical activity

to increase the body resistance to stresses (hypoxia, hyperthermia, hypothermia)

during sudden changes in climatic conditions, adaptation to atmospheric pressure changes

Route of administration

For the treatment of ARVI as part of complex therapy

8-day course

Form and dosage

Trekrezan® tablets (18+)

Day 1 x 3

Next days x1

For the prevention of ARVI as part of complex therapy

14-day course

Form and dosage

Trekrezan® tablets (18+)

x 1

Trekrezan® – different formats for different needs

1 complete course of ARVI treatment

1 complete course of ARVI prevention

for the treatment of ARVI in several family members

THERE ARE CONTRAINDICATIONS. IT IS NECESSARY TO CONSULT A HEALTHCARE PROFESSIONAL.

Trekrezan® package leaflet No. ЛСР-008909/09

1 — Shabanov P.D., Zarubina I.V., Mokrenko E.V. Pharmacology of Trekrezan – a new immunomodulator and adaptogen. 2014, p. 3–20.

2 — Malinnikova E.Yu. et al. Results of an observational study of Trekrezan® efficacy and safety in adult patients with acute respiratory viral infection (ARVI). Therapy 8, 2021.

3 — Zueva I.B. et al. How to optimize the management of patients with post-infectious asthenia who have recovered from COVID-19 at the outpatient stage? Therapy 6, 2021.